Cocarnit in female patients with ischemic placental disease in the postpartum period
DOI: 10.32364/2618-8430-2023-6-4-10
Yu.E. Dobrokhotova, L.S. Dzhokhadze
Pirogov Russian National Research Medical University, Moscow, Russian Federation
Ischemic placental disease, which includes such nosological entities as preeclampsia, fetal growth retardation and placental abruption, is commonly the cause of premature labor, which makes it an urgent medical and biological problem. To increase the efficacy of preventive measures, it seems promising to use metabolic therapy, which implies a direct effect on metabolic processes at the tissue and cellular levels. The antioxidant effect of metabolic drugs can reduce the formation of reactive oxygen species and peroxyl radicals in the blood and tissues, and prevent cellular damage. The authors present their experience concerning the use of Cocarnit® metabolic drug, which includes triphosadenine, cocarboxylase, cyanocobalamin and nicotinamide, in complex therapy in the late postpartum period in patients with ischemic placental disease. The use of this drug improves the hemodynamic parameter control, normalizes carbohydrate metabolism, contributes to the rapid restoration of hemoglobin levels in combination with iron preparations, as well as to a softer and faster rehabilitation of female patients in this group, increasing the probability of a favorable outcome in future pregnancy. It should be noted that the preliminary results obtained by the authors require further randomized comparative clinical trials on large samples.
Keywords: pregnancy, ischemic placental disease, postpartum period, fetal death, Cocarnit, triphosadenine, cocarboxylase, nicotinamide, cyanocobalamin, metabolic therapy.
For citation: Dobrokhotova Yu.E., Dzhokhadze L.S. Cocarnit in female patients with ischemic placental disease in the postpartum period. Russian Journal of Woman and Child Health. 2023;6(4):385–390 (in Russ.). DOI: 10.32364/2618-8430-2023-6-4-10.
About the authors:
Yulia E. Dobrokhotova — Dr. Sc. (Med.), Professor, Head of the Department of Obstetrics and Gynecology of the Medical Faculty, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117997, Russian Federation; ORCID iD 0000-0002-7830-2290.
Lela S. Dzhokhadze — C. Sc. (Med.), Associate Professor of the Department of Obstetrics and Gynecology, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117997, Russian Federation; ORCID iD 0000-0001-5389-7817.
Contact information: Yulia E. Dobrokhotova, e-mail: pr.dobrohotova@mail.ru.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 20.09.2023.
Revised 11.10.2023.
Accepted 09.11.2023.
2. Johnson K.M., Smith L., Modest A.M. et al. Angiogenic factors and prediction for ischemic placental disease in future pregnancies. Pregnancy Hypertens. 2021;25:12–17. DOI: 10.1016/j.preghy.2021.05.011.
3. Roberts J.M. Pathophysiology of ischemic placental disease. Semin Perinatol. 2014;38(3):139–145. DOI: 10.1053/j.semperi.2014.03.005.
4. Evers A.C., van Rijn B.B., van Rossum M.M., Bruinse H.W. Subsequent pregnancy outcome after first pregnancy with normotensive early-onset intrauterine growth restriction at <34 weeks of gestation. Hypertens Pregnancy. 2011;30(1):37–44. DOI: 10.3109/10641955.2010.484080.
5. Madazli R., Yuksel M.A, Imamoglu M. et al. Comparison of clinical and perinatal outcomes in early- and late-onset preeclampsia. Arch Gynecol Obstet. 2014;290(1):53–57. DOI: 10.1007/s00404-014-3176-x.
6. Haddad B., Deis S., Goffinet F. et al. Maternal and perinatal outcomes during expectant management of 239 severe preeclamptic women between 24 and 33 weeks' gestation. Am J Obstet Gynecol. 2004;190(6):1590–1595; discussion 1595–1597. DOI: 10.1016/j.ajog.2004.03.050.
7. Rezk M., Gamal A., Emara M. Maternal and Fetal Outcome in de Novo Preeclampsia in Comparison to Superimposed Preeclampsia: A Two-Year Observational Study. Hypertens. Pregnancy. 2015;34(2):137–144. DOI: 10.3109/10641955.2014.982329.
8. Sibai B.M., Koch M.A., Freire S. et al. The impact of prior preeclampsia on the risk of superimposed preeclampsia and other adverse pregnancy outcomes in patients with chronic hypertension. Am J Obstet Gynecol. 2011;204(4):345.e1–345.e6. DOI: 10.1016/j.ajog.2010.11.027.
9. Литвинова Т.И., Петельский Ю.В., Анацко С.В. Применение кардио-нейропротектора Кокарнит в комплексном лечении пациентов с артериальной гипертонией 1 степени. В кн.: Тезисы XIV Всероссийского конгресса «Артериальная гипертония 2018: на перекрестке мнений». 2018:66. [Litvinova T.I., Petel'skiy Yu.V., Anatsko S.V. Application of the cadoneuroprotector Cocarnit in the complex treatment of patients with arterial hypertension of the 1st degree. In: Abstracts of the XIV All-Russian Congress “Arterial Hypertension 2018: at the crossroads of opinions.” 2018:66 (in Russ.)].
10. Ходжаева У.З., Юсупов А.Ф., Миррахимова С.Ш., Миркомило Э.М. Оценка клинической эффективности препаратов медотилин и Кокарнит в комплексном лечении глазного ишемического синдрома. Глаз. 2015;5(105):27–29. [Khodzhayeva U.Z., Yusupov A.F., Mirrakhimova S.Sh., Mirkomilo E.M. Evaluation of the clinical effectiveness of medotilin and Cocarnit in the complex treatment of ocular ischemic syndrome. Glaz. 2015;5(105):27–29 (in Russ.)].
11. Котов С.В., Исакова Е.В., Лиждвой В.Ю. и др. Эффективность препарата кокарнит при диабетической нейропатии. Журнал неврологии и психиатрии им. С.С. Корсакова. 2018;118(1):37–42. DOI: 10.17116/jnevro20181181137-42. [Kotov S.V., Isakova E.V., Lizhdvoĭ V.Iu. et al. The efficacy of cocarnit in diabetic neuropathy. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2018;118(1):37–42 (in Russ.)]. DOI: 10.17116/jnevro20181181137-42.
12. Мкртумян А.М., Оранская А.Н. Кокарнит — высокоэффективный и безопасный подход к терапии диабетической нейропатии. Эффективная фармакотерапия. 2022;18(10):10–16. DOI: 10.33978/2307-3586-2022-18-10-10-16. [Mkrtumyan A.M., Oranskaya A.N. Cocarnit — Highly Effective and Safe Approach to the Treatment of Diabetic Neuropathy. Effektivnaya farmakoterapiya. 2022;18(10):10–16 (in Russ.)]. DOI: 10.33978/2307-3586-2022-18-10-10-16.
13. Пашкова И.Н., Потупчик Т.В., Гацких И.В. и др. Оценка эффективности метаболической терапии в лечении диабетической полинейропатии у больных с сахарным диабетом 2 типа. Вопросы биологической, медицинской и фармацевтической химии. 2020;23(10):25–34. DOI: 10.29296/25877313-2020-10-0. [Pashkova I.N., Potupchik T.V., Gackich I.V. et al. Evaluation of the effectiveness of metabolic therapy in the treatment of diabetic polyneuropathies in patients with type 2 diabetes. Problems of biological, medical and pharmaceutical chemistry. 2020;23(10):25–34 (in Russ.)]. DOI: 10.29296/25877313-2020-10-04.
14. Ханюков А.А., Ягудина Е.Д., Григоренко О.Г., Осипчук И.Н. Клинический опыт использования Кокарнита в комплексном лечении пациентов с ИБС и ХСН. Кардиология. 2019;2(447):18–19. [Khanyukov A.A., Yagudina Ye.D., Grigorenko O.G., Osipchuk I.N. Clinical experience of using Cocarnit in the complex treatment of patients with coronary heart disease and heart failure. Kardiologiya. 2019;2(447):18–19 (in Russ.)].
15. Ших Е.В., Петунина Н.А., Недосугова Л.В. и др. Спонтанная и индуцированная секреция провоспалительных и противовоспалительных цитокинов у пациентов с сахарным диабетом 2 типа и синдромом диабетической стопы. Сахарный диабет. 2020;23(3):210–222. DOI: 10.14341/DM12343. [Shikh E.V., Petunina N.A., Nedosugova L.V. et al. Spontaneous and induced secretion of the pro-inflammatory and anti-inflammatory cytokines in patients with type 2 diabetes mellitus and diabetic foot syndrome. Diabetes mellitus. 2020;23(3):210–222 (in Russ.)]. DOI: 10.14341/DM12343.
16. Можейко Л.Ф., Коршикова Р.Л., Савицкая В.М. и др. Новые возможности лечения фетоплацентарной недостаточности. Репродуктивное здоровье в Беларуси. 2010;5:75–81. [Mozheyko L.F., Korshikova R.L., Savitskaya V.M. et al. New possibilities for the treatment of fetoplacental insufficiency. Reproduktivnoye zdorov'ye v Belarusi. 2010;5:75–81 (in Russ.)].
17. Мкртумян А.М., Маркова Т.Н., Подачина С.В. Возможность применения препарата Кокарнит при лечении диабетической полинейропатии комплексным препаратом Кокарнит. Эффективная фармакотерапия. 2016;4-5:6–10. [Mkrtumyan A.M., Markova T.N., Podachina S.V. The Possibility of Using Coсarnit Drug in the Treatment of Diabetic Polyneuropathy. Effektivnaya farmakoterapiya. 2016;4-5:6–10 (in Russ.)].
18. Рачин А.П., Шаров М.Н. Сравнительное открытое рандомизированное исследование по оценке эффективности и безопасности применения препарата Кокарнит при боли в спине у пациентов, страдающих диабетической полиневропатией. РМЖ. 2017;9:586–590. [Rachin A.P., Sharov M.N. Comparative opened randomized study on assessment of efficiency and safety of the use of Cocarnit in patients with diabetic polyneuropathy. RMJ. 2017;9:586–590 (in Russ.)].
19. Парфенов В.А., Головачева В.А., Фадеев В.В. и др. Оптимизация ведения пациентов с диабетической полиневропатией с помощью меж-дисциплинарного подхода. Медицинский совет. 2017;1S:71–79. DOI: 10.21518/2079-701X-2017-0-71-79. [Parfenov V.A., Golovacheva V.A., Fadeev V.V. et al. Optimization diabetic polyneuropathy patients management using a multidisciplinary approach. Meditsinskiy sovet. 2017;1S:71–79 (in Russ.)]. DOI: 10.21518/2079-701X-2017-0-71-79.
20. Морозова О.Г., Ярошевский А.А., Здыбский В.И., Липинская Я.В. Клинико-патогенетическая взаимосвязь вегетативной и мио-фасциальной дисфункции (оценка эффективности применения препарата Кокарнит). Международный неврологический журнал. 2013;1(55):75–80. [Morozova O.G., Yaroshevskiy A.A., Zdybskiy V.I., Lipinskaya Ya.V. Clinical and pathogenetic relationship between autonomic and myofascial dysfunction (evaluation of the effectiveness of the drug Cocarnit). International Neurological Journal. 2013;1(55):75–80 (in Russ.)].
21. Терещенко Ю.В., Ахмедов В.А., Лялюков А.В. Диастолическая функция сердца и вегетативная регуляция работы сердечно-сосудистой системы как опорные точки приложения для метаболической поддержки на фоне регулярного тренировочного процесса. Международный журнал прикладных и фундаментальных исследований. 2021;3:40–45. DOI: 10.17513/mjpfi.13189. [Tereshchenko YU.V., Akhmedov V.A., Lyalyukov A.V. Diastolic heart function and autonomic regulation of the cardiovascular system as reference points for metabolic support against the background of a regular training process. Mezhdunarodnyy zhurnal prikladnykh i fundamental'nykh issledovaniy. 2021;3:40–45 (in Russ.)]. DOI: 10.17513/mjpfi.13189.
This work is licensed under a Creative Commons «Attribution» 4.0 License.
